Skip to main content

Compare Stocks

Date Range: 

 Kala PharmaceuticalsAkebia TherapeuticsViking TherapeuticsInozyme PharmaSummit Therapeutics
SymbolNASDAQ:KALANASDAQ:AKBANASDAQ:VKTXNASDAQ:INZYNASDAQ:SMMT
Price Information
Current Price$5.19$3.44$6.14$15.79$5.49
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.71.71.61.70.4
Analysis Score3.43.33.63.50.0
Community Score2.62.73.52.82.2
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.81.70.0
Earnings & Valuation Score0.60.60.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$21.33$7.83$16.89$36.00N/A
% Upside from Price Target311.05% upside127.71% upside175.06% upside127.99% upsideN/A
Trade Information
Market Cap$329.03 million$533.18 million$462.35 million$356.57 million$450.29 million
Beta0.432.112.02N/A0.87
Average Volume2,360,0075,596,9741,264,10357,213184,306
Sales & Book Value
Annual Revenue$6.07 million$335 millionN/AN/A$56.50 million
Price / Sales55.271.64N/AN/A8.06
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.86 per share$3.32 per share$3.83 per shareN/A$0.50 per share
Price / Book6.031.04N/AN/A10.98
Profitability
Net Income$-94,350,000.00$-279,660,000.00$-25,780,000.00N/A$9.99 million
EPS($2.76)($1.63)($0.36)N/AN/A
Trailing P/E RatioN/AN/AN/A0.000.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-1,794.36%-126.86%N/AN/A-933.62%
Return on Equity (ROE)-93.73%-68.51%-13.57%N/A-100.94%
Return on Assets (ROA)-43.09%-34.01%-13.14%N/A-71.52%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.68%0.24%N/AN/AN/A
Current Ratio9.11%2.15%27.08%16.71%2.85%
Quick Ratio8.73%1.67%27.09%16.71%2.85%
Ownership Information
Institutional Ownership Percentage67.63%68.98%54.13%69.77%9.50%
Insider Ownership Percentage34.15%2.55%3.70%N/AN/A
Miscellaneous
Employees188379183879
Shares Outstanding64.64 million160.12 million78.10 million23.47 million82.93 million
Next Earnings Date8/5/2021 (Estimated)8/9/2021 (Estimated)8/4/2021 (Estimated)9/2/2021 (Estimated)N/A
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Summit Therapeutics Publishes Scientific Updates to Corporate WebsiteSummit Therapeutics Publishes Scientific Updates to Corporate Website
finance.yahoo.com - May 6 at 8:55 AM
Summit Therapeutics Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights OfferingSummit Therapeutics' Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
benzinga.com - May 5 at 12:57 PM
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $6.37Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $6.37
americanbankingnews.com - May 3 at 1:36 PM
Summit Therapeutics Inc. (NASDAQ:SMMT) Short Interest UpdateSummit Therapeutics Inc. (NASDAQ:SMMT) Short Interest Update
americanbankingnews.com - May 1 at 12:08 PM
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $6.25Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $6.25
americanbankingnews.com - April 30 at 11:39 AM
Summit Therapeutics Announces Rights OfferingSummit Therapeutics Announces Rights Offering
finance.yahoo.com - March 26 at 7:26 AM
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter ...Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter ...
apnews.com - March 18 at 8:22 AM
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
finance.yahoo.com - March 17 at 9:42 AM
Can You Get A Quick Recovery From Summit Therapeutics Inc. (NASDAQ:SMMT) Given A -0.45% Drop From High?Can You Get A Quick Recovery From Summit Therapeutics Inc. (NASDAQ:SMMT) Given A -0.45% Drop From High?
marketingsentinel.com - February 7 at 7:45 PM
Summit Therapeutics Plc Share ChatSummit Therapeutics Plc Share Chat
lse.co.uk - February 6 at 6:05 PM
Summit Therapeutics Inc.Summit Therapeutics Inc.
barrons.com - January 9 at 10:36 PM
Kaskela Law LLC Announces Investigation of Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Contact the FirmKaskela Law LLC Announces Investigation of Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Contact the Firm
finance.yahoo.com - December 19 at 5:51 PM
Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% HigherSummit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher
finance.yahoo.com - December 16 at 2:10 PM
Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating OfficerSummit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer
finance.yahoo.com - November 23 at 7:56 AM
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter ...Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter ...
apnews.com - November 17 at 3:03 PM
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020
finance.yahoo.com - November 16 at 6:58 PM
Prime Minister calls halt to trade talks with BrusselsPrime Minister calls halt to trade talks with Brussels
msn.com - October 16 at 6:02 PM
Johnson calls halt to trade talks with BrusselsJohnson calls halt to trade talks with Brussels
msn.com - October 16 at 1:01 PM
When is the official UK ban on new petrol, diesel and hybrid car sales?When is the official UK ban on new petrol, diesel and hybrid car sales?
uk.news.yahoo.com - October 8 at 1:44 PM
Summit Therapeutics Inc (SMMT) USD0.01Summit Therapeutics Inc (SMMT) USD0.01
hl.co.uk - September 24 at 7:05 PM
Why Summit Therapeutics Shares Climbed 12.9% TodayWhy Summit Therapeutics Shares Climbed 12.9% Today
sg.finance.yahoo.com - September 12 at 7:15 PM
Is Summits Ridinilazole a Threat to Acurxs Ibezapolstat in the C.difficile Space?Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space?
streetwisereports.com - August 10 at 11:46 PM
How long until COVID-19 bounce back? Auto industry leaders debateHow long until COVID-19 bounce back? Auto industry leaders debate
am-online.com - August 10 at 8:45 AM
Summit Therapeutics plc (SMMT)Summit Therapeutics plc (SMMT)
ca.finance.yahoo.com - August 4 at 6:01 PM
Summit Announces Intention to Redomicile its Holding Company to the United StatesSummit Announces Intention to Redomicile its Holding Company to the United States
finance.yahoo.com - July 16 at 7:28 AM
DateCompanyBrokerageAction
5/12/2021Kala PharmaceuticalsHC WainwrightLower Price Target
11/30/2020Kala PharmaceuticalsNorthland SecuritiesReiterated Rating
10/28/2020Kala PharmaceuticalsWedbushBoost Price Target
9/14/2020Kala PharmaceuticalsJefferies Financial GroupDowngrade
5/29/2020Kala PharmaceuticalsOppenheimerInitiated Coverage
5/27/2020Kala PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
3/15/2021Akebia TherapeuticsCantor FitzgeraldInitiated Coverage
9/4/2020Akebia TherapeuticsMorgan StanleyLower Price Target
9/4/2020Akebia TherapeuticsBTIG ResearchLower Price Target
9/4/2020Akebia TherapeuticsMizuhoLower Price Target
8/11/2020Akebia TherapeuticsNeedham & Company LLCInitiated Coverage
5/6/2020Akebia TherapeuticsRoyal Bank of CanadaBoost Price Target
5/3/2021Viking TherapeuticsSVB LeerinkReiterated Rating
1/22/2021Viking TherapeuticsStifel NicolausReiterated Rating
10/29/2020Viking TherapeuticsRaymond JamesBoost Price Target
9/11/2020Viking TherapeuticsWilliam BlairReiterated Rating
9/10/2020Viking TherapeuticsB. RileyReiterated Rating
8/31/2020Viking TherapeuticsChardan CapitalBoost Price Target
6/4/2020Viking TherapeuticsBMO Capital MarketsInitiated Coverage
5/2/2020Viking TherapeuticsMaxim GroupInitiated Coverage
8/18/2020Inozyme PharmaBank of AmericaInitiated Coverage
8/18/2020Inozyme PharmaPiper SandlerInitiated Coverage
8/18/2020Inozyme PharmaCowenInitiated Coverage
8/16/2018Summit TherapeuticsCanaccord GenuitySet Price Target
6/28/2018Summit TherapeuticsJanney Montgomery ScottDowngrade
6/28/2018Summit TherapeuticsJMP SecuritiesDowngrade
6/27/2018Summit TherapeuticsUBS GroupDowngrade
6/27/2018Summit TherapeuticsSunTrust BanksDowngrade
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.